We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




GE Healthcare Forms Biomolecular Imaging Alliance with Fujifilm

By MedImaging International staff writers
Posted on 17 Jun 2009
Print article
GE Healthcare (Chalfont St. Giles, UK), a unit of General Electric Co. (Fairfield, CT, USA), has entered into a strategic alliance agreement with Fujifilm Corp. (Tokyo, Japan). Under the terms of alliance, Fujifilm will develop, manufacture, and supply advanced biomolecular-imaging systems to GE Healthcare. The products will be sold worldwide under the GE brand in the life science research and drug discovery markets.

Life science research has advanced rapidly in recent years with the advent of tools for genomic and protein research such as biomolecular labeling, detection, and analysis. These technologies have helped reveal the functions of proteins, thereby contributing to scientists' understanding of disease processes. The use of life science instrumentation and reagents in bioscience research is growing, and the demand for new and innovative enabling technologies is expanding.

In 1987, Fujifilm was the first company to introduce the innovative digital autoradiography device, which utilized the imaging plate, a radiation detector with sensitivity 100 times greater than X-ray film. Since then, Fujifilm has utilized its chemical and optical technologies cultivated in the field of photo imaging to launch a wide range of instruments, including innovative charged coupled device (CCD) camera systems, contributing to the advancement of imaging in genomic and protein research.

In 1923, GE Healthcare introduced the first radioisotope reagents, which initiated the field of biomolecular labeling and detection. Since then, GE Healthcare has introduced a series of nonradioactive detection reagents, such as ECL and CyDyes, to enable safe and quantitative biomolecular labeling, detection, and analysis. The company's system solutions have radically improved the way scientists can analyze gene and protein expression in tissues and cells.

"This deal represents an important progression for our business,” stated Yuzo Toda, director, corporate vice president, general manager of life science products division, Fujifilm. "By forming the alliance, both companies will make the most of our complementary capabilities to continue to contribute to the advancement of genomic and protein research, and to help enhance the quality of life of people worldwide. GE Healthcare's global presence as a supplier of reagents and instruments, and its competence in biological applications within the life science field combined with Fujifilm's leading imaging technologies, R&D and manufacturing capabilities will provide our customers with comprehensive system solutions for research, drug discovery and bioanalytical applications.”

"We are delighted to work with Fujifilm to expand our support to bioscience research in biomolecular imaging system solutions,” said Nigel Darby, general manager of biotechnologies, life sciences, GE Healthcare. "Fujifilm‘s high-quality technology platforms fit well with our proprietary labeling technologies and the adjacent fields in the imaging workflow that GE Healthcare currently addresses. Furthermore, the integration of the imaging platform with our global service organization will give strong and valuable customer support.”

Fujifilm will supply image-analyzing systems for bioscience research to GE Healthcare, and GE Healthcare will market and sell them under the GE brand. GE Healthcare will be responsible for marketing/sales of the systems worldwide, and will provide total solutions including instruments, electrochemiluminescence (ECL) and differential in-gel electrophoresis (DIGE) labeling reagents, and applications support. Additionally, GE Healthcare will provide instrument services for the systems. Lastly, Fujifilm and GE Healthcare will collaborate to develop image-analyzing systems that are optimized for customer applications.

GE Healthcare provides transformational medical technologies and services for patient care. The company's expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help in delivering better care to more people worldwide.

Fujifilm is one of the major operating companies of Fujifilm Holdings. The company is now applying these their expertise in film technologies to the prevention, diagnosis, and treatment of diseases in the medical and life science fields. Fujifilm is also expanding growth in the highly functional materials business, including flat panel display materials, and in the graphic systems and optical devices businesses.

Related Links:

GE Healthcare
Fujifilm


New
Gold Member
X-Ray QA Meter
T3 AD Pro
Portable X-ray Unit
AJEX130HN
Silver Member
Radiographic Positioning Equipment
2-Step Multiview Positioning Platform
New
Portable Color Doppler Ultrasound System
S5000

Print article
Radcal

Channels

Radiography

view channel
Image: The new X-ray detector produces a high-quality radiograph (Photo courtesy of ACS Central Science 2024, DOI: https://doi.org/10.1021/acscentsci.4c01296)

Highly Sensitive, Foldable Detector to Make X-Rays Safer

X-rays are widely used in diagnostic testing and industrial monitoring, from dental checkups to airport luggage scans. However, these high-energy rays emit ionizing radiation, which can pose risks after... Read more

MRI

view channel
Image: The scans revealed a new dimension of brain network organization in humans (Photo courtesy of Georgia State University/TReNDS Center Research)

New Approach Identifies Signatures of Chronic Brain Disorders Using fMRI Scans

Traditional studies of brain function, often using fMRI scans to detect brain activity patterns, have shown promise in identifying changes in individuals with chronic brain disorders like schizophrenia.... Read more

Nuclear Medicine

view channel
Image: Example of AI analysis of PET/CT images (Photo courtesy of Academic Radiology; DOI: 10.1016/j.acra.2024.08.043)

AI Analysis of PET/CT Images Predicts Side Effects of Immunotherapy in Lung Cancer

Immunotherapy has significantly advanced the treatment of primary lung cancer, but it can sometimes lead to a severe side effect known as interstitial lung disease. This condition is characterized by lung... Read more

General/Advanced Imaging

view channel
Image: Cleerly offers an AI-enabled CCTA solution for personalized, precise and measurable assessment of plaque, stenosis and ischemia (Photo courtesy of Cleerly)

AI-Enabled Plaque Assessments Help Cardiologists Identify High-Risk CAD Patients

Groundbreaking research has shown that a non-invasive, artificial intelligence (AI)-based analysis of cardiac computed tomography (CT) can predict severe heart-related events in patients exhibiting symptoms... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.